BioMimetic Therapeutics Submits Augment Bone Graft PMA Amendment to FDA

BioMimetic Therapeutics, Inc. BMTI announced today that it has submitted to the Food and Drug Administration (FDA) an amendment to its Pre-Market Approval (PMA) application for Augment^® Bone Graft for its use as an alternative to autograft in hindfoot and ankle fusion procedures. The amendment provides supplemental information requested by the FDA in a post-panel response letter announced by the Company earlier this year.